In general, pharmacological TRAF6 inhibition with component 6877002 was not only analyzed in obesity or atherosclerotic mouse models, but was also found to be a potential therapeutic strategy in other inflammatory or autoimmune diseases like neuroinflammation/multiple sclerosis (Aarts et al., 2017), breast cancer (Bishop et al., 2020), bone cancer (Marino et al., 2022) and in heart failure (Bosch et al., 2019; Marino et al., 2022). Here, TRAF6 is linked to obesity disorder.